20197-86-8

Basic information

• Product Name: 2-CHLORO-6,7-DIMETHOXY-3H-QUINAZOLIN-4-ONE
• Synonyms: 2-CHLORO-6,7-DIMETHOXY-3H-QUINAZOLIN-4-ONE;IFLAB-BB F2108-0139;2-chloro-6,7-diMethoxyquinazolin-4(3H)-one;2-chloro-6,7-diMethoxy-4(3H)-quinazolinone;2-Chloro-6,7-dimethoxy-1H-quinazolin-4-one
• CAS NO: 20197-86-8
• Molecular Formula: C₁₀H₉ClN₂O₃
• Molecular Weight: 240.64
• Mol File: 20197-86-8.mol
• Article Data: 7

Chemical Properties

• Melting Point: 270-272℃
• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-CHLORO-6,7-DIMETHOXY-3H-QUINAZOLIN-4-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-6,7-DIMETHOXY-3H-QUINAZOLIN-4-ONE(20197-86-8)
• EPA Substance Registry System: 2-CHLORO-6,7-DIMETHOXY-3H-QUINAZOLIN-4-ONE(20197-86-8)

Safety Data

• Hazardous Substances Data: 20197-86-8(Hazardous Substances Data)

Usage

Description

2-CHLORO-6,7-DIMETHOXY-3H-QUINAZOLIN-4-ONE is an organic compound with the molecular formula C10H9ClN2O3. It is a derivative of quinazolinone, a heterocyclic compound with potential applications in various fields due to its unique chemical structure and properties.

Uses

Used in Pharmaceutical Industry:
2-CHLORO-6,7-DIMETHOXY-3H-QUINAZOLIN-4-ONE is used as a reactant for the synthesis of Alogliptin, a potent and selective inhibitor of the serine protease dipeptidyl peptidase IV (DPP-IV). Alogliptin is an important drug used in the treatment of type 2 diabetes, as it helps to control blood sugar levels by increasing the levels of insulin and decreasing the levels of glucagon in the body. The compound's role in the synthesis of Alogliptin highlights its significance in the development of therapeutic agents for managing diabetes.

Upstream product

• 27631-29-4 2-chloro-6,7-dimethoxy-3H-quinazolin-4-one 

Downstream Products

• 100448-62-2 4-(6,7-Dimethoxy-4-oxo-3,4-dihydro-quinazolin-2-ylamino)-benzoic acid 
• 20198-40-7 6,7-dimethoxy-2-(N-phenylamino)quinazolin-4-one 
• 20198-38-3 2-benzylamino-6,7-dimethoxy-3H-quinazolin-4-one 
• 105150-92-3 6,7-Dimethoxy-2-[3-(3-piperidin-1-ylmethyl-phenoxy)-propylamino]-3H-quinazolin-4-one 
• 16175-61-4 2-(Dimethylamino)-6,7-dimethoxy-3,4-dihydro-4-chinazolinon 
• 769158-08-9 2-((2-chloro-6,7-dimethoxy-4-oxoquinazolin-3(4H)-yl)methyl)benzonitrile 
• 129112-53-4 6,7-Dimethoxy-2-(4-methyl-piperazin-1-yl)-4-phenoxy-quinazoline 
• 828242-08-6 6,7-dimethoxy-2-[methyl-(3-pyrrolidin-1-yl-benzyl)-amino]-1H-quinazolin-4-one 
• 441065-09-4 6,7-dimethoxy-2-(1-m-tolyl-1,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-3H-quinazolin-4-one 
• 441065-09-4 6,7-Dimethoxy-2-(1-m-tolyl-1,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-1H-quinazolin-4-one 
• 441065-08-3 2-(1-benzyl-1,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-6,7-dimethoxy-3H-quinazolin-4-one 
• 1227169-98-3 4-Benzyl-1-(4-hydroxy-6,7-dimethoxy-quinazolin-2-yl)-piperidine-4-carboxylic acid ethyl ester 

Relevant articles and documents

ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 INHIBITORS,COMPOSITIONS AND USES THEREOF

The present invention relates to compounds of Formula (I), methods of using the compounds as ENPP1 inhibitors, and pharmaceutical compositions comprising such compounds.The compounds are useful in treating cancers and infectious diseases.

Pyrimidinone compounds

This invention relates to treating inflammatory and immune diseases with certain pyrimidinone compounds that bind to CXCR3 receptors. The pyrimidinone compounds are covered by the formula (I) shown below. Each variable is defined in the specification.

Structure-activity relationships of novel 2-substituted quinazoline antibacterial agents

High-throughput screening of in-house compound libraries led to the discovery of a novel antibacterial agent, compound 1 (MIC: 12-25 μM against S. pyogenes). In an effort to improve the activity of this active compound, a series of 2-substituted quinazolines was synthesized and evaluated in several antibacterial assays. One such compound (22) displayed improved broad- spectrum antibacterial activity against a variety of bacterial strains. This molecule also inhibited transcription/translation of bacterial RNA, suggesting a mechanism for its antibiotic effects. Structure-activity relationship studies of 22 led to the synthesis of another 24 compounds. Although some of these molecules were found to be active in bacterial growth assays, none were as potent as 22. Compound 22 was tested for its ability to cure a systemic K. pneumonia infection in the mouse and displayed moderate effects compared with a control antibiotic, gentamycin.